Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer (Paperback)
6 Angebote vergleichen
Bester Preis: Fr. 59.54 (€ 60.84)¹ (vom 29.10.2019)1
Symbolbild
Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer (2015)
DE PB NW RP
ISBN: 9783659709623 bzw. 365970962X, in Deutsch, LAP Lambert Academic Publishing Jul 2015, Taschenbuch, neu, Nachdruck.
Von Händler/Antiquariat, AHA-BUCH GmbH [51283250], Einbeck, Germany.
This item is printed on demand - Print on Demand Titel. Neuware - Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 % and 30 % of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g. 3 nM). Further NCI screenings exhibited a good cytostatic inhibitory profile for all tested compounds. 264 pp. Englisch.
This item is printed on demand - Print on Demand Titel. Neuware - Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 % and 30 % of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g. 3 nM). Further NCI screenings exhibited a good cytostatic inhibitory profile for all tested compounds. 264 pp. Englisch.
2
Symbolbild
Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer (Paperback) (2015)
DE PB NW RP
ISBN: 9783659709623 bzw. 365970962X, in Deutsch, LAP Lambert Academic Publishing, United States, Taschenbuch, neu, Nachdruck.
Von Händler/Antiquariat, The Book Depository EURO [60485773], London, United Kingdom.
Language: English Brand New Book ***** Print on Demand *****.Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 and 30 of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g.
Language: English Brand New Book ***** Print on Demand *****.Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 and 30 of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g.
3
Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer - Synthesis, Characterisation, Structure-Activity-Relationship, Biological Analysis and Application
~EN PB NW
ISBN: 9783659709623 bzw. 365970962X, vermutlich in Englisch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer: Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 % and 30 % of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g. 3 nM). Further NCI screenings exhibited a good cytostatic inhibitory profile for all tested compounds. Englisch, Taschenbuch.
Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer: Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 % and 30 % of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g. 3 nM). Further NCI screenings exhibited a good cytostatic inhibitory profile for all tested compounds. Englisch, Taschenbuch.
4
Symbolbild
Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer
DE NW
ISBN: 9783659709623 bzw. 365970962X, in Deutsch, neu.
Lieferung aus: Deutschland, zzgl. Versandkosten.
Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 % and 30 % of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g. 3 nM). Further NCI screenings exhibited a good cytostatic inhibitory profile for all tested compounds.
Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 % and 30 % of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g. 3 nM). Further NCI screenings exhibited a good cytostatic inhibitory profile for all tested compounds.
5
Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer
~EN NW AB
ISBN: 9783659709623 bzw. 365970962X, vermutlich in Englisch, neu, Hörbuch.
Lieferung aus: Österreich, Lieferzeit: 5 Tage, zzgl. Versandkosten.
Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 % and 30 % of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g. 3 nM). Further NCI screenings exhibited a good cytostatic inhibitory profile for all tested compounds.
Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of cancer death, and the leading cause of cancer death in women. Protein kinases regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, they are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6), a non-receptor tyrosine kinase, as well as the Epidermal Growth Factor Receptors (EGFR), particularly HER2, were initially cloned from a metastatic breast tumor, are overexpressed in 86 % and 30 % of human breast tumors and several breast cancer cell lines, respectively. Subsequently, targeting these two protein kinases is assumed to be of interest in breast cancer therapeutical survey. Novel -carboline derivatives have been synthesized and biologically investigated against both Brk and HER2 kinases which showed a very promising inhibitory profile in low nanomolar IC50 concentrations (e.g. 3 nM). Further NCI screenings exhibited a good cytostatic inhibitory profile for all tested compounds.
6
Novel Protein Kinase Inhibitors as New Therapeutics for Breast Cancer
~EN NW
ISBN: 365970962X bzw. 9783659709623, vermutlich in Englisch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…